Seeking Alpha

Covidien (COV) issues FY13 guidance, saying it expects revenues to increase 3% to 6% over the...

Covidien (COV) issues FY13 guidance, saying it expects revenues to increase 3% to 6% over the prior year, and its plans to spin off its pharmaceuticals business into a stand-alone public company are on track. Pharmaceutical sales are projected to be up 1% to 4%, and 4% to 7% in its medical devices segment. Operating margins should be in the 22% to 23% range with an effective tax rate of 18% to 19%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector